VA
CNTA

VR Adviser’s Centessa Pharmaceuticals CNTA Stock Holding History

VR Adviser’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-411,361
Closed -$3.69M – 30
2022
Q1 		$3.69M Sell
411,361
-715,911
-64% -$6.53M 0.6% 24
2021
Q4 		$12.7M Hold
1,127,272
– – 1.74% 18
2021
Q3 		$18.8M Hold
1,127,272
– – 2.42% 14
2021
Q2 		$25M Buy
+1,127,272
New +$26.5M 3.04% 13

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

VR Adviser's CNTA Position: Q2 2022 in Review

VR Adviser sold out of Centessa Pharmaceuticals (CNTA) in Q2 2022, closing a stake of 411,361 shares — an estimated $3.69M sold.

VR Adviser first reported a position in CNTA in Q2 2021 and held it in 4 quarters. The position peaked at $25M in Q2 2021. 41 funds tracked by Wall St. Rank hold CNTA as of Q2 2022.

  • VR Adviser reported no remaining Centessa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • VR Adviser sold 411,361 Centessa Pharmaceuticals shares in Q2 2022, an estimated $3.69M.
  • VR Adviser first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • VR Adviser's Centessa Pharmaceuticals position peaked at $25M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2022.

Based on VR Adviser's 13F filing for Q2 2022, filed 15 Aug 2022.